Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability

Objectives: Concerns regarding the clinical impact of meropenem instability in continuous infusion (CI) devices may contribute to inconsistent uptake of this method of administration across outpatient parenteral antimicrobial therapy (OPAT) services. Methods: We retrospectively reviewed the clinical...

Full description

Bibliographic Details
Main Authors: Manning, L., Wright, Cameron, Ingram, P., Whitmore, T., Heath, C., Manson, I., Page-Sharp, Madhu, Salman, S., Dyer, J., Davis, T.
Format: Journal Article
Published: Public Library of Science 2014
Subjects:
Online Access:http://hdl.handle.net/20.500.11937/38670
_version_ 1848755383243374592
author Manning, L.
Wright, Cameron
Ingram, P.
Whitmore, T.
Heath, C.
Manson, I.
Page-Sharp, Madhu
Salman, S.
Dyer, J.
Davis, T.
author_facet Manning, L.
Wright, Cameron
Ingram, P.
Whitmore, T.
Heath, C.
Manson, I.
Page-Sharp, Madhu
Salman, S.
Dyer, J.
Davis, T.
author_sort Manning, L.
building Curtin Institutional Repository
collection Online Access
description Objectives: Concerns regarding the clinical impact of meropenem instability in continuous infusion (CI) devices may contribute to inconsistent uptake of this method of administration across outpatient parenteral antimicrobial therapy (OPAT) services. Methods: We retrospectively reviewed the clinical efficacy and safety of CIs of meropenem in two Australian tertiary hospitals and assessed its stability under simulated OPAT conditions including in elastomeric infusion devices containing 1% (2.4 g) or 2% (4.8 g) concentrations at either ‘room temperature’ or ‘cooled’ conditions. Infusate aliquots were assayed at different time-points over 24 hours. Results: Forty-one (82%) of 50 patients had clinical improvement or were cured. Adverse patient outcomes including hemato-, hepato- and nephrotoxicity were infrequent. Cooled infusers with 1% meropenem had a mean 24-hour recovery of 90.3%. Recoveries of 1% and 2% meropenem at room temperature and 2% under cooled conditions were 88%, 83% and 87%, respectively. Patients receiving 1% meropenem are likely to receive >95% of the maximum deliverable dose (MDD) over a 24-hour period whilst patients receiving 2% meropenem should receive 93% and 87% of the MDD under cooled and room temperature conditions, respectively. Conclusions: Meropenem infusers are likely to deliver ~95% MDD and maintain effective plasma concentrations throughout the dosing period. These data reflect our local favourable clinical experience with eropenem CIs.
first_indexed 2025-11-14T08:55:26Z
format Journal Article
id curtin-20.500.11937-38670
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:55:26Z
publishDate 2014
publisher Public Library of Science
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-386702017-11-28T07:43:23Z Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability Manning, L. Wright, Cameron Ingram, P. Whitmore, T. Heath, C. Manson, I. Page-Sharp, Madhu Salman, S. Dyer, J. Davis, T. pseudomonas aeruginosa renal system toxicity antimicrobials blood plasma Antibiotics pharmacokinetics gram negative bacteria Objectives: Concerns regarding the clinical impact of meropenem instability in continuous infusion (CI) devices may contribute to inconsistent uptake of this method of administration across outpatient parenteral antimicrobial therapy (OPAT) services. Methods: We retrospectively reviewed the clinical efficacy and safety of CIs of meropenem in two Australian tertiary hospitals and assessed its stability under simulated OPAT conditions including in elastomeric infusion devices containing 1% (2.4 g) or 2% (4.8 g) concentrations at either ‘room temperature’ or ‘cooled’ conditions. Infusate aliquots were assayed at different time-points over 24 hours. Results: Forty-one (82%) of 50 patients had clinical improvement or were cured. Adverse patient outcomes including hemato-, hepato- and nephrotoxicity were infrequent. Cooled infusers with 1% meropenem had a mean 24-hour recovery of 90.3%. Recoveries of 1% and 2% meropenem at room temperature and 2% under cooled conditions were 88%, 83% and 87%, respectively. Patients receiving 1% meropenem are likely to receive >95% of the maximum deliverable dose (MDD) over a 24-hour period whilst patients receiving 2% meropenem should receive 93% and 87% of the MDD under cooled and room temperature conditions, respectively. Conclusions: Meropenem infusers are likely to deliver ~95% MDD and maintain effective plasma concentrations throughout the dosing period. These data reflect our local favourable clinical experience with eropenem CIs. 2014 Journal Article http://hdl.handle.net/20.500.11937/38670 10.1371/journal.pone.0102023.g002 http://creativecommons.org/licenses/by/4.0/ Public Library of Science fulltext
spellingShingle pseudomonas aeruginosa
renal system
toxicity
antimicrobials
blood plasma
Antibiotics
pharmacokinetics
gram negative bacteria
Manning, L.
Wright, Cameron
Ingram, P.
Whitmore, T.
Heath, C.
Manson, I.
Page-Sharp, Madhu
Salman, S.
Dyer, J.
Davis, T.
Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability
title Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability
title_full Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability
title_fullStr Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability
title_full_unstemmed Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability
title_short Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability
title_sort continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability
topic pseudomonas aeruginosa
renal system
toxicity
antimicrobials
blood plasma
Antibiotics
pharmacokinetics
gram negative bacteria
url http://hdl.handle.net/20.500.11937/38670